Back

Fractional versus standard BNT162b2 boosters after non-mRNA priming in Mongolia: 24-month immunogenicity and safety evidence from a randomised controlled trial

2025-09-07 epidemiology Title + abstract only
View on medRxiv
Show abstract

BackgroundBooster doses of COVID-19 vaccines help restore protection against waning immunity and emerging variants. Having found that fractional BNT162b2 boosters were non-inferior to standard boosters in eliciting anti-spike IgG responses at day 28 in Mongolian adults, we assessed long-term immunogenicity and safety in the same cohort. MethodsIn this randomised, controlled, non-inferiority trial, adults previously vaccinated with two doses of ChAdOx1-S, BBIBP-CorV, or Gam-COVID-Vac were random...

Predicted journal destinations